» Articles » PMID: 30830877

Lkb1 Deletion in Periosteal Mesenchymal Progenitors Induces Osteogenic Tumors Through MTORC1 Activation

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2019 Mar 5
PMID 30830877
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Bone osteogenic sarcoma has a poor prognosis as the exact cell of origin and the signaling pathways underling tumor formation remain undefined. Here, we report an osteogenic tumor mouse model based on the conditional knockout of liver kinase b1 (Lkb1; also known as Stk11) in Cathepsin K (Ctsk)-Cre expressing cells. Lineage tracing studies demonstrated that Ctsk-Cre could label a population of periosteal cells. The cells functioned as mesenchymal progenitors with regard to markers and functional properties. LKB1 deficiency increased proliferation and osteoblast differentiation of Ctsk+ periosteal cells, while downregulation of mTORC1 activity, using Raptor genetic mouse model or mTORC1 inhibitor treatment, ameliorated tumor progression of Ctsk-Cre Lkb1fllfl mice. Xenograft mouse models, using human osteosarcoma cell lines, also demonstrated that LKB1 deficiency promoted tumor formation, while mTOR inhibition suppressed xenograft tumor growth. In summary, we identified periosteum-derived Ctsk-Cre expressing cells as a cell of origin for osteogenic tumor and suggested the LKB1-mTORC1 pathway as a promising target for treatment of osteogenic tumor.

Citing Articles

Cathepsin K inhibition promotes efficient differentiation of human embryonic stem cells to mature cardiomyocytes by mediating glucolipid metabolism and cellular energy homeostasis.

Wang Y, Cui Y, Liu X, Liang S, Zhong L, Guo R Stem Cell Res Ther. 2025; 16(1):118.

PMID: 40045408 PMC: 11883997. DOI: 10.1186/s13287-025-04231-7.


Apolipoprotein E is a marker of all chondrocytes in the growth plate resting zone.

Kodama J, Oichi T, Wilkinson K, Abzug J, Kaito T, Enomoto-Iwamoto M Bone Res. 2025; 13(1):31.

PMID: 40025030 PMC: 11873292. DOI: 10.1038/s41413-025-00407-2.


Nuclear farnesoid X receptor protects against bone loss by driving osteoblast differentiation through stabilizing RUNX2.

Dong Q, Fu H, Li W, Ji X, Yin Y, Zhang Y Bone Res. 2025; 13(1):20.

PMID: 39885145 PMC: 11782663. DOI: 10.1038/s41413-024-00394-w.


Signaling pathway mechanisms of circadian clock gene Bmal1 regulating bone and cartilage metabolism: a review.

Ze Y, Wu Y, Tan Z, Li R, Li R, Gao W Bone Res. 2025; 13(1):19.

PMID: 39870641 PMC: 11772753. DOI: 10.1038/s41413-025-00403-6.


Insights into targeting LKB1 in tumorigenesis.

Trelford C, Shepherd T Genes Dis. 2024; 12(2):101402.

PMID: 39735555 PMC: 11681833. DOI: 10.1016/j.gendis.2024.101402.


References
1.
Dempster D, Compston J, Drezner M, Glorieux F, Kanis J, Malluche H . Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2012; 28(1):2-17. PMC: 3672237. DOI: 10.1002/jbmr.1805. View

2.
Walkley C, Qudsi R, Sankaran V, Perry J, Gostissa M, Roth S . Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22(12):1662-76. PMC: 2428063. DOI: 10.1101/gad.1656808. View

3.
Ji H, Ramsey M, Hayes D, Fan C, McNamara K, Kozlowski P . LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448(7155):807-10. DOI: 10.1038/nature06030. View

4.
Korsse S, Peppelenbosch M, van Veelen W . Targeting LKB1 signaling in cancer. Biochim Biophys Acta. 2013; 1835(2):194-210. DOI: 10.1016/j.bbcan.2012.12.006. View

5.
Martin-Broto J, Redondo A, Valverde C, Vaz M, Mora J, Garcia Del Muro X . Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017; 28(12):2994-2999. DOI: 10.1093/annonc/mdx536. View